Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

bioAffinity Technologies (BIAF) EBIAT (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBIAT for 4 consecutive years, with -$3.1 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 5.75% to -$3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.9 million through Dec 2025, down 64.93% year-over-year, with the annual reading at -$14.9 million for FY2025, 64.93% down from the prior year.
  • EBIAT for Q4 2025 was -$3.1 million at bioAffinity Technologies, up from -$5.1 million in the prior quarter.
  • The five-year high for EBIAT was -$88052.0 in Q2 2022, with the low at -$5.1 million in Q3 2025.
  • Average EBIAT over 4 years is -$2.5 million, with a median of -$2.2 million recorded in 2023.
  • Peak annual rise in EBIAT hit 53.43% in 2023, while the deepest fall reached 1876.3% in 2023.
  • Over 4 years, EBIAT stood at -$1.7 million in 2022, then tumbled by 41.72% to -$2.4 million in 2023, then decreased by 25.02% to -$3.0 million in 2024, then decreased by 5.75% to -$3.1 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$3.1 million, -$5.1 million, and -$4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.